The collaboration began in January 2021 and has been focused on using Cline's gradient surface technology and methodology to develop protocols for differentiation of induced pluripotent stem (iPS) cells into cell types relevant for the repair and treatment of vascular anomalies. Creating such cell types will allow researchers to understand the core mechanisms of vascular disease and help to develop new treatments. 

About V.A Cure
V.A Cure is a Horizon 2020 funded project that aims to uncover core mechanisms of vascular anomalies and leverage this information to establish new therapeutics for vascular disease. The project consists of 14 individual research projects across seven academic labs and two industry partners. 

Vascular anomalies (https://vascern.eu/expertise/rare-diseases-wgs/vasca-wg/#1601982596181-d6d20da1-90b5) are defects of the vascular system that can be either with blood or lymph vessels. Many vascular anomalies are congenial and inherited, but they can also be brought on by events such as trauma and pregnancy. In addition, vascular anomalies can be malformations or tumors, ranging from harmless to life-threatening. 

Cline Scientific is a member of AstraZeneca's BioVentureHub in Gothenburg, Sweden. 
For more information about V.A Cure, follow the link to https://vacure.eu/. 
For more information, please contact:
Patrik Sundh, CEO
Email: patrik.sundh@clinescientific.com 
Phone: +46 0703585088